ONK Therapeutics

ONK Therapeutics is a pioneering biotechnology research company dedicated to developing a next-generation of off-the-shelf, dual-targeted NK cell therapy platform, aiming to cure patients with cancer. Located in Galway, Ireland, ONK Therapeutics is focused on hematological malignancies and solid tumors, positioning itself at the forefront of innovative cell therapies.

Founded in 2015, ONK Therapeutics' core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e., DR4 or DR5). This approach has the potential to enhance efficacy by addressing both intrinsic and extrinsic apoptotic pathways, reducing susceptibility to target antigen escape through tumor antigen-independent TRAILv engagement.

ONK Therapeutics is committed to advancing cancer treatment through its novel NK cell therapies. The company's Galway address reflects its dedication to cutting-edge research and development in the biotechnology sector. We invite the manager of ONK Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.